Alexander Niecke1, Klaus Peters, Christina Samel, Kristin Forster, Markus Lüngen, Holger Pfaff, Christian Albus. 1. Department of Psychosomatics and Psychotherapy, University Hospital Cologne; Department of Orthopedics and Osteology, Dr. Becker Rhein-Sieg-Klinik Nümbrecht; Institute of Medical Statistics, Informatics and Epidemiology and Institute for Health Economics and Clinical Epidemiology, University of Cologne; Faculty of Business Management and Social Sciences, Osnabrück University of Applied Sciences; Institute of Medical Sociology, Health Services Research, and Rehabilitation Science (IMVR), University of Cologne & University Hospital Cologne.
Abstract
BACKGROUND: More than 50 years after the withdrawal of thalidomide from the market, subsequent orthopedic damages and psychosocial impairments dominate the complaints of thalidomide-affected individuals. The aim of the study was to determine the prevalence of mental disorders in this group. METHODS: A total of 193 thalidomide-affected individuals from North Rhine-Westphalia (mean age 50.5 years, 56.5% women) underwent personal and comprehensive psychodiagnostic testing, which was based on the Structured Clinical Interview for DSM-IV disorders (SCID-I & SCID-II) and self-reporting questionnaires. RESULTS: Overall, the four-week prevalence of mental disorders was 47.2%. Multiple mental disorders were present in 45.1% among the 91 participants with diagnosed mental disorders. The most frequent diagnoses were unipolar depressive disorders (16.5%), somatoform disorders (14.0%), phobic disorders (12.4%), and alcohol-related disorders (6.2%). Immediate mental health care was indicated in 80.2% of participants with current mental disorders, but only 29.7% had used some form of psychosocial treatment in the 12 months preceding the study. CONCLUSION: Mental disorders occur approximately twice as often (relative risk [RR]: 1.77; 95% confidence interval [1.49; 2.10]) in thalidomide-affected individuals as in the age-matched German population. Together with a very low rate of utilization of mental health care, this finding implies an underuse of psychosocial healthcare. The development of specialized psychosocial treatment services may remove barriers that impede access to the healthcare system.
BACKGROUND: More than 50 years after the withdrawal of thalidomide from the market, subsequent orthopedic damages and psychosocial impairments dominate the complaints of thalidomide-affected individuals. The aim of the study was to determine the prevalence of mental disorders in this group. METHODS: A total of 193 thalidomide-affected individuals from North Rhine-Westphalia (mean age 50.5 years, 56.5% women) underwent personal and comprehensive psychodiagnostic testing, which was based on the Structured Clinical Interview for DSM-IV disorders (SCID-I & SCID-II) and self-reporting questionnaires. RESULTS: Overall, the four-week prevalence of mental disorders was 47.2%. Multiple mental disorders were present in 45.1% among the 91 participants with diagnosed mental disorders. The most frequent diagnoses were unipolar depressive disorders (16.5%), somatoform disorders (14.0%), phobic disorders (12.4%), and alcohol-related disorders (6.2%). Immediate mental health care was indicated in 80.2% of participants with current mental disorders, but only 29.7% had used some form of psychosocial treatment in the 12 months preceding the study. CONCLUSION:Mental disorders occur approximately twice as often (relative risk [RR]: 1.77; 95% confidence interval [1.49; 2.10]) in thalidomide-affected individuals as in the age-matched German population. Together with a very low rate of utilization of mental health care, this finding implies an underuse of psychosocial healthcare. The development of specialized psychosocial treatment services may remove barriers that impede access to the healthcare system.
Authors: Martin Härter; Harald Baumeister; Katrin Reuter; Frank Jacobi; Michael Höfler; Jürgen Bengel; Hans-Ulrich Wittchen Journal: Psychother Psychosom Date: 2007 Impact factor: 17.659
Authors: Frank Jacobi; Michael Höfler; Jens Siegert; Simon Mack; Anja Gerschler; Lucie Scholl; Markus A Busch; Ulfert Hapke; Ulrike Maske; Ingeburg Seiffert; Wolfgang Gaebel; Wolfgang Maier; Michael Wagner; Jürgen Zielasek; Hans-Ulrich Wittchen Journal: Int J Methods Psychiatr Res Date: 2014-04-11 Impact factor: 4.035
Authors: Christina Samel; Christian Albus; Irmgard Nippert; Alexander Niecke; Markus Lüngen; Holger Pfaff; Klaus M Peters Journal: BMC Womens Health Date: 2019-04-03 Impact factor: 2.809